Healios K K (4593)

Currency in JPY
224.0
+1.0(+0.45%)
Closed·
Earnings results expected in 3 days
4593 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
220.0238.0
52 wk Range
208.0499.0
Key Statistics
Bid/Ask
222.00 / 225.00
Prev. Close
224
Open
231
Day's Range
220-238
52 wk Range
208-499
Volume
1.85M
Average Vol. (3m)
1.82M
1-Year Change
-52.0343%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4593 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
794.8
Upside
+254.84%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Healios K K News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 794.8
(+254.84% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Nomura/Instinet
Buy660.00+194.64%640.00MaintainJun 05, 2026
Chardan
Buy800.00+257.14%-New CoverageApr 07, 2026
Cantor Fitzgerald
Buy---New CoverageMar 17, 2026
UBS
Buy800.00+257.14%-MaintainDec 29, 2025

Earnings

Latest Release
Aug 12, 2026
EPS / Forecast
10.13 / -2.90
Revenue / Forecast
7M / 24.33M
EPS Revisions
Last 90 days

4593 Income Statement

Compare 4593 to Peers and Sector

Metrics to compare
4593
Peers
Sector
Relationship
P/E Ratio
146.7x−6.7x−0.2x
PEG Ratio
1.67−0.140.00
Price / Book
3.5x3.0x2.6x
Price / LTM Sales
514.6x13.6x2.8x
Upside (Analyst Target)
254.8%90.2%60.9%
Fair Value Upside
Unlock6.8%9.5%Unlock

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer(solid tumors). It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.51M4.80%1.45B
Other Institutional Investors
46.25M34.12%10.31B
Public Companies & Retail Investors
82.79M61.08%18.46B
Total
135.55M100.00%30.23B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Athos Capital Limited23.32%31,615,8007,050,323
Morgan Stanley5.39%7,302,3311,628,420

People Also Watch

295.0
7777
-0.34%
10.00
PRAKIT
-1.96%
4.20
PICOm
0.00%
695.0
7746
+3.73%
657.00
4896
+6.83%

FAQ

What Is the Healios K K (4593) Stock Price Today?

The Healios K K stock price today is 224.0 JPY.

What Stock Exchange Does Healios K K Trade On?

Healios K K is listed and trades on the Tokyo Stock Exchange.

What Is the Stock Symbol for Healios K K?

The stock symbol for Healios K K is "4593."

What Is the Healios K K Market Cap?

As of today, Healios K K market cap is 30.36B JPY.

What Is Healios K K's Earnings Per Share (TTM)?

The Healios K K EPS (TTM) is 1.69.

When Is the Next Healios K K Earnings Date?

Healios K K will release its next earnings report on Nov 12, 2026.

From a Technical Analysis Perspective, Is 4593 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Healios K K Stock Split?

Healios K K has split 0 times.

How Many Employees Does Healios K K Have?

Healios K K has 75 employees.

What is the current trading status of Healios K K (4593)?

As of Nov 09, 2026, Healios K K (4593) is trading at a price of 224.0 JPY, with a previous close of 224.0 JPY. The stock has fluctuated within a day range of 220.0 JPY to 238.0 JPY, while its 52-week range spans from 208.0 JPY to 499.0 JPY.

What Is Healios K K (4593) Price Target According to Analysts?

The average 12-month price target for Healios K K is 794.8 JPY, with a high estimate of 1289 JPY and a low estimate of 510 JPY. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +254.84% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.